作者
Balakrishnan Chakrapani Narmada,Atefeh Khakpoor,Niranjan Shirgaonkar,Sriram Narayanan,Pauline Aw,Malay Singh,Kok Haur Ong,Collins Oduor Owino,Jane Wei Ting Ng,Hui Chuing Yew,Nu Soibah Binte Mohamed Nasir,Bijin Au,Reina Sng,Nivashini Kaliaperumal,Htet Htet Toe Wai Khine,Francesca Casuscelli di Tocco,Masayuki Otsuka,J Shamita Naikar,Hui Xin Ng,Su Li Chia,Cindy Xin Yi Seah,Myra HJ. Alnawaz,Chris Lee Yoon Wai,Amy Yuh Ling Tay,Mangat Kamarjit Singh,Valerie Chew,Weimiao Yu,John E. Connolly,Giridharan Periyasamy,Marie‐Laure Plissonnier,Massimo Levrero,Seng Gee Lim,Ramanuj DasGupta
摘要
Abstract
Background & Aims
Hepatitis B surface antigen (HBsAg) loss or functional cure (FC), is considered the desirable therapeutic outcome for chronic hepatitis B (CHB) patients. However, the immune-pathological biomarkers and underlying mechanisms remain unclear. In this study we comprehensively interrogate disease-associated cell states (DACS) identified within intra-hepatic tissue and matched PBMCs from either CHB or FC patients, at the resolution of single cells, to provide novel insights into putative mechanisms underlying FC. Methods
We combined single cell transcriptomics (scRNA-seq) with multiparametric flow cytometry-based immune phenotyping, and multiplexed immunofluorescence to elucidate the immunopathological cell states associated with CHB vs FC. Results
We find that the intra-hepatic environment of CHB and FC patients displays specific cell identities and molecular signatures that are distinct from those found in matched PBMCs. FC is associated with emergence of an altered adaptive immune response marked by CD4 cytotoxic T lymphocytes (CD4-CTLs), and an activated innate response represented by liver-resident natural killer (LR-NK) cells, specific Kupffer cell (KC) subtypes and marginated neutrophils. Surprisingly, we find that FC patients are also characterized by the presence of MHC class II-expressing hepatocytes and low but persistent levels of cccDNA and pgRNA, which may play an important role in achieving functional cure in HBV patients. Conclusions
Our study provides conceptually novel insights into the immuno-pathological control of HBV cure, and opens exciting new avenues for clinical management, biomarker discovery and therapeutic interventions. We believe that the discoveries from this study, as it relates to the activation of an innate and altered immune response that may facilitate sustained, low-grade inflammation, may have broader implications in the resolution of chronic viral hepatitis.